The American College of Physicians has formally recommended the use of the respiratory syncytial virus (RSV) vaccine for older adults, marking a pivotal development in preventive medicine. The guidance targets vulnerable populations, particularly individuals aged 60 and above, who face heightened risk of severe respiratory complications. The recommendation reflects growing clinical evidence supporting vaccine efficacy and safety. Public health analysts suggest the move could reshape adult immunization protocols while generating substantial activity in the global vaccine market.